Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13377947 | 0.78 | ALDH1A1 (0.43) | ALDH1A1 | |
| SCHEMBL874433 | 0.73 | L3MBTL1 (0.43) | ALDH1A1 | |
| SCHEMBL898825 | 0.73 | POLB (0.47) | ALDH1A1 | |
| SCHEMBL13378024 | 0.72 | KDM4E (0.47) | ALDH1A1 | |
| SCHEMBL2344594 | 0.68 | POLB (0.46) | ALDH1A1 | |
| SCHEMBL2339880 | 0.68 | L3MBTL1 (0.42) | ALDH1A1 | |
| SCHEMBL3871185 | 0.62 | — | — | |
| SCHEMBL21564771 | 0.60 | — | — | |
| SCHEMBL30416191 | 0.59 | KDM4E (0.32) | ALDH1A1 | |
| SCHEMBL13142398 | 0.57 | PTGS1 (0.42) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11351274-B2 | Methods of using optical agents | MEDIBEACON INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20220127237-A1 | FLUORESCENT PYRAZINE DERIVATIVES AND METHODS OF USING THE SAME IN ASSESSING RENAL FUNCTION | MEDIBEACON INC. | 2022-04-28 | — | — | US | disclosed |
| US-11185597-B2 | Process for using optical agents | MEDIBEACON, INC. (US) | 2021-11-30 | — | — | US | disclosed |
| US-10695445-B2 | Methods of using optical agents | MEDIBEACON INC. (US) | 2020-06-30 | — | — | US | disclosed |
| US-10617687-B2 | Fluorescent pyrazine derivatives and methods of using the same in assessing renal function | MEDIBEACON INC. (US) | 2020-04-14 | — | — | US | disclosed |
| US-20190192696-A1 | METHODS OF USING OPTICAL AGENTS | MALLINCKRODT LLC | 2019-06-27 | — | — | US | disclosed |
| US-20190192695-A1 | PROCESS FOR USING OPTICAL AGENTS | MALLINCKRODT LLC | 2019-06-27 | — | — | US | disclosed |
| US-20190022256-A1 | METHODS OF USING OPTICAL AGENTS | MALLINCKRODT LLC | 2019-01-24 | — | — | US | disclosed |
| US-20170298030-A9 | FLUORESCENT PYRAZINE DERIVATIVES AND METHODS OF USING THE SAME IN ASSESSING RENAL FUNCTION | Medibeacon, LLC | 2017-10-19 | — | — | US | disclosed |
| US-20160280666-A1 | FLUORESCENT PYRAZINE DERIVATIVES AND METHODS OF USING THE SAME IN ASSESSING RENAL FUNCTION | MEDIBEACON INC (US) | 2016-09-29 | — | — | US | disclosed |
| US-20140039191-A1 | Fluorescent Pyrazine Derivatives and Methods of Using the Same in Assessing Renal Function | Medibeacon, LLC (US) | 2014-02-06 | — | — | US | disclosed |
| EP-1986701-B1 | OPTICAL AGENTS FOR USE IN SURGERY | MALLINCKRODT LLC (US) | 2012-06-13 | — | — | EP | disclosed |
| EP-2135863-A1 | Fluorescent pyrazine derivatives and methods of using the same in assessing renal function | Mallinckrodt, Inc. (US) | 2009-12-23 | — | — | EP | disclosed |
| EP-2039688-A1 | Fluorescent pyrazine derivatives and methods of using the same in assessing renal function | Mallinckrodt, Inc. (US) | 2009-03-25 | — | — | EP | disclosed |
| US-20090010851-A1 | Fluorescent Pyrazine Derivatives and Methods of Using the Same in Assessing Renal Function | MALLINCKRODT INC. (US) | 2009-01-08 | — | — | US | disclosed |
| US-20090010851-A1 | Fluorescent Pyrazine Derivatives and Methods of Using the Same in Assessing Renal Function | MALLINCKRODT INC. (US) | 2009-01-08 | — | — | US | disclosed |
| US-20080312539-A1 | Methods of Using Optical Agents | MEDIBEACON, INC. | 2008-12-18 | — | — | US | disclosed |
| US-20080312539-A1 | Methods of Using Optical Agents | MEDIBEACON, INC. | 2008-12-18 | — | — | US | disclosed |
| EP-1854790-A1 | Fluorescent pyrazine derivatives and methods of using the same in assessing renal function | Mallinckrodt, Inc. (US) | 2007-11-14 | — | — | EP | disclosed |
| WO-2007106142-A2 | PROCESS FOR USING OPTICAL AGENTS | MALLINCKRODT INC. (US) | 2007-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220127237-A1 | FLUORESCENT PYRAZINE DERIVATIVES AND METHODS OF USING THE SAME IN ASSESSING RENAL FUNCTION | GLS, XDH, CYP4F12 | ALDH1A1 546/4885 |
| US-10617687-B2 | Fluorescent pyrazine derivatives and methods of using the same in assessing renal function | GLS, CYP4F12, XDH | ALDH1A1 393/4885 |
| US-20160280666-A1 | FLUORESCENT PYRAZINE DERIVATIVES AND METHODS OF USING THE SAME IN ASSESSING RENAL FUNCTION | GLS, CYP4F12, XDH | ALDH1A1 393/4885 |
| US-10695445-B2 | Methods of using optical agents | REN, ATP6V1B1, VHL | ALDH1A1 2024/4885 |
| US-20170298030-A9 | FLUORESCENT PYRAZINE DERIVATIVES AND METHODS OF USING THE SAME IN ASSESSING RENAL FUNCTION | GLS, CYP4F12, XDH | ALDH1A1 393/4885 |
| US-20190022256-A1 | METHODS OF USING OPTICAL AGENTS | REN, ATP6V1B1, VHL | ALDH1A1 2024/4885 |
| US-20190192695-A1 | PROCESS FOR USING OPTICAL AGENTS | REN, ATP6V1B1, VHL | ALDH1A1 1866/4885 |
| US-20090010851-A1 | Fluorescent Pyrazine Derivatives and Methods of Using the Same in Assessing Renal Function | GLS, CYP4F12, XDH | ALDH1A1 393/4885 |
| US-20140039191-A1 | Fluorescent Pyrazine Derivatives and Methods of Using the Same in Assessing Renal Function | GLS, CYP4F12, XDH | ALDH1A1 393/4885 |
| US-11185597-B2 | Process for using optical agents | REN, ATP6V1B1, VHL | ALDH1A1 1866/4885 |
| US-11351274-B2 | Methods of using optical agents | REN, ATP6V1B1, VHL | ALDH1A1 2024/4885 |
| US-20190192696-A1 | METHODS OF USING OPTICAL AGENTS | REN, ATP6V1B1, VHL | ALDH1A1 2024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.